On November 18, Gelonghui reported that Tainkang (301263.SZ) recently stated in an investor relations event that the company's eye drops containing pilocarpine hydrochloride for treating presbyopia in adults received approval for clinical trials in March 2024, with the first subject enrolled in June 2024. The clinical trials are currently proceeding as planned, and the company will strive to advance the clinical progress, aiming to complete the enrollment of all patients by the end of this year; as of now, there are no similar products approved for sale in the domestic market.
泰恩康(301263.SZ)：目前盐酸毛果芸香碱滴眼液临床试验按计划进行中，争取在今年年底前完成全部患者入组
Tianenkang (301263.SZ): Currently, the clinical trials for atropine eye drops are progressing as planned, aiming to complete the enrollment of all patients by the end of this year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
[2025.2] How should NVIDIA's performance be viewed? The key indicator to watch for short-term stock prices is this.
NVIDIA has been one of the best-performing Technology giants in the US stock market over the past two years, and since 2024, its stock price has experienced sig
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th